Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Status:
Completed
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
Myeloproliferative neoplasms (MPN) such as Polycythemia Vera (PV) and, Essential
Thrombocythaemia (ET) are rare clonal myeloid neoplasms associated with an increased risk of
both venous and arterial thrombosis. Thrombotic complications are the main determinant of
morbidity and in a less extend mortality.
Routine haemostasis analysis (TP, aPTT) are usually normal and are useless to demonstrate a
hypercoagulable state. However, previous evidence suggests that global coagulation tests such
as thrombin generation or thromboelastometry are able to detect signs of procoagulant
imbalance in MPN. Similarly, current data seems to demonstrate that fibrin clot properties
(clot permeability, turbidimetry, clot lysis time) properties is altered suggesting an
hypercoagulable state.
Goals of PV and ET treatments are to control blood count to reduce the risk of thrombotic
events. Moreover, new drugs such as Janus Kinase Inhibitors (JAKi) were recently licensed for
PV and are under investigations on clinical trial for ET. It is currently unknown if
treatments that were used for ET and PV, and especially JAKi are able to modify the
hypercoagulable state that is observed in those diseases, and if there is difference between
drugs.
To evaluate impact of MPN treatment on prothrombotic haemostatic profile, we propose to
evaluate global coagulation and fibrin clot properties in MPN, depending on the treatment.